Last reviewed · How we verify
NCT04057638
Craniomaxillofacial and Upper Extremity Allotransplantation
NA trial testing Combined Craniomaxillofacial and Upper Extremity Allotransplantation in Face Injuries in 10 participants. Currently enrolling.
1 January 2026
Quick facts
| Lead sponsor | NYU Langone Health |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 17 June 2019 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 January 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Combined Craniomaxillofacial and Upper Extremity Allotransplantation
Conditions studied
- Face Injuries — all drugs for Face Injuries →
- Hand Injuries — all drugs for Hand Injuries →
- Craniofacial Injuries — all drugs for Craniofacial Injuries →
- Upper Extremity Injuries — all drugs for Upper Extremity Injuries →
Sponsor
NYU Langone Health — full company profile →
Who can join
Adults 18 to 64, any sex, with Face Injuries or Hand Injuries. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic devices.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Combined Whole Eye and Face Transplant: Microsurgical Strategy and 1-Year Clinical Course.
Ceradini DJ, Tran DL, Dedania VS, Gelb BE, et al · · 2024 · cited 23× · PMID 39250113 · DOI 10.1001/jama.2024.12601
Verify or expand the search:
- PubMed search for NCT04057638
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other NYU Langone Health trials
Trials by the same sponsor.
- NCT07214519 — Permanent Supportive Housing Overdose Prevention-2 Study · NA · not yet recruiting
- NCT05558267 — Potassium Containing Salt-Substitute in Hemodialysis-Dependent End Stage Kidney Disease · NA · not yet recruiting
- NCT06637852 — Sexual and Urinary Function Improvement for Cancer Survivors · NA · not yet recruiting
- NCT06236087 — Overdose Prevention Centers and Behavioral Health · not yet recruiting
- NCT06462027 — Packed Red Blood Cell Transfusion During Cardiac Arrest · Phase 1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04057638 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by NYU Langone Health
- Last refreshed: 16 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04057638.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing